Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Oehler

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Nature Cancer|June 10, 2021
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemiaJeevisha Bajaj, Michael Hamilton, Yutaka Shima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Nature Cancer|June 10, 2021
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemiaJeevisha Bajaj, Michael Hamilton, Yutaka Shima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
European Journal of Haematology|September 6, 2023
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemiaLucas C Zarling, Philip A Stevenson, Lorinda A Soma, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2015
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council reportFabiana Ostronoff, Megan Othus, Michelle Lazenby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Transplantation and Cellular Therapy|May 6, 2024
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid NeoplasmsNoam E Kopmar, Megan Othus, Kim Quach, et al.
Haematologica|November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasmsAnna B Halpern, Megan Othus, Emily M Huebner, et al.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Pageof 11